iBio, Inc. has added a proprietary biotherapeutic product for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis to its product pipeline. iBio obtained license to patents and related intellectual property for this novel therapy, and then entered a collaboration agreement with the Medical University of South Carolina (MUSC), the inventor and now the Kitty Trask Holt and SmartState SC Centers of Economic Excellence Endowed Professor at MUSC, that will enable iBio to advance the development of a potentially breakthrough biotherapeutic product against these otherwise unstoppable diseases. Effective treatment of IPF, systemic sclerosis and localized scleroderma, represents an unmet medical need.

Although some limited results have been claimed for existing therapies, there are currently no effective therapies for stopping or reversing fibrosis.